Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene

25 Jan 2017

Abstract excerpt

A subset of HER2+ breast cancer patients manifest clinical resistance to trastuzumab. Recently, miR-26a and miR-30b have been identified as trastuzumab response regulators, and their target gene CCNE2 seems to play an important role in resistance to trastuzumab therapy. Cell viability was evaluated in trastuzumab treated HER2+ BT474 wt (sensitive), BT474r (acquired resistance), HCC1954 (innate resistance), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28120942
DOI: 10.1038/srep41309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 genePMID 28120942Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancerSemantic proximity Read ↗

Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in ResistanceSemantic proximity Read ↗

Unveiling the Molecular Mechanism of Trastuzumab Resistance in SKBR3 and BT474 Cell Lines for HER2 Positive Breast CancerSemantic proximity Read ↗

Identification of autophagy related genes predicting response of trastuzumab resistance in breast cancer patientsSemantic proximity Read ↗

mRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancer.Semantic proximity Read ↗

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.Semantic proximity Read ↗

Proteomic Characterization of a 3D HER2+ Breast Cancer Model Reveals the Role of Mitochondrial Complex I in Acquired Resistance to TrastuzumabSemantic proximity Read ↗

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancerSemantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.